ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
120.445,91
0,15%
S&P 500
5.473,17
-0,25%
US Dollar vs BRL
5,4538
0,00%
Bitcoin
64.623,59
-0,30%
Brent Oil
84,99
-0,02%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Fractyl Health Inc (GUTS)

  7. Fractyl Health Inc (GUTS) Notícias

GUTS

Fractyl Health (GUTS)

Fractyl Health Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GUTS
DataHoraFonteTítuloCódigoCompanhia
29/05/202408:00GlobeNewswire Inc.Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific SessionsNASDAQ:GUTSFractyl Health Inc
20/05/202407:00GlobeNewswire Inc.Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024NASDAQ:GUTSFractyl Health Inc
14/05/202417:15Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:GUTSFractyl Health Inc
13/05/202417:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GUTSFractyl Health Inc
13/05/202417:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GUTSFractyl Health Inc
13/05/202417:00GlobeNewswire Inc.Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:GUTSFractyl Health Inc
13/05/202407:00GlobeNewswire Inc.Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)NASDAQ:GUTSFractyl Health Inc
08/05/202407:00GlobeNewswire Inc.Fractyl Health to Present at BofA Securities 2024 Health Care ConferenceNASDAQ:GUTSFractyl Health Inc
07/05/202407:00GlobeNewswire Inc.Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024NASDAQ:GUTSFractyl Health Inc
30/04/202409:38GlobeNewswire Inc.Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual MeetingNASDAQ:GUTSFractyl Health Inc
02/04/202409:00GlobeNewswire Inc.Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 DiabetesNASDAQ:GUTSFractyl Health Inc
01/04/202408:00GlobeNewswire Inc.Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:GUTSFractyl Health Inc
01/04/202407:00GlobeNewswire Inc.Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based DrugsNASDAQ:GUTSFractyl Health Inc
12/03/202415:06GlobeNewswire Inc.UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and ObesityNASDAQ:GUTSFractyl Health Inc
12/03/202409:38GlobeNewswire Inc.Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and ObesityNASDAQ:GUTSFractyl Health Inc
20/02/202410:38GlobeNewswire Inc.Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical TrialsNASDAQ:GUTSFractyl Health Inc
01/02/202422:08GlobeNewswire Inc.Fractyl Health Announces Pricing of Initial Public OfferingNASDAQ:GUTSFractyl Health Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:GUTS

Seu Histórico Recente

COIN
IAGUST
IAGON
USOTC
XYIGF
Xinyi Glass (PK)
LSE
LVNG
Rize Enviro Etf
AMEX
GBR
New Concept Energy
TG
A3K8XY
Siemens
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados